• Skip to main content
  • Skip to main content
Choose which site to search.
University of Arkansas for Medical Sciences Logo University of Arkansas for Medical Sciences
Winthrop P. Rockefeller Cancer Institute: Patients and Family
  • UAMS Health
  • Jobs
  • Giving
  • Finding Your Way
    • Prepare for Your First Visit
    • Maps and Directions
    • Accommodations
    • Dining
    • Gift Shop
    • Services & Amenities
  • Treatment
    • Cancer Institute Clinical Resources
    • Clinical Trials
    • Clinics and Centers
    • myChart
    • Appointments
    • Cancer Types
    • Treatment Options
    • Cancer Survivorship Programs
  • Prevention
    • Genetics Program
    • Quit Smoking Programs
    • Lung Cancer Screening
    • Colorectal Cancer Screenings
    • MammoVan
  • Patient Support
    • Support Groups
    • Social Workers
    • Financial Counseling
    • Pharmacist
    • Cancer Nutrition Services
    • Pastoral Care
  1. University of Arkansas for Medical Sciences
  2. Winthrop P. Rockefeller Cancer Institute
  3. Patients and Family
  4. A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Clonidine Mucoadhesive Buccal Tablet to Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Patients with Oropharyngeal Cancer

A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Clonidine Mucoadhesive Buccal Tablet to Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Patients with Oropharyngeal Cancer

PI: Dr. Gary Lewis

Sponsor: Monopar Therapeutics 

This study is being performed to evaluate the effectiveness of a new drug, clonidine HCl MBT, to prevent the onset of severe oral mucositis (SOM) in patients with oropharyngeal cancer (OPC) who are being treated with chemoradiotherapy. OPC occurs on the back of the tongue or throat and is often treated by the use of chemoradiotherapy, where radiation is localized to these areas. Radiation to the OPC affected tissues causes the release of small proteins called cytokines that cause damage to the area surrounding the tumor including the oral cavity.

This damage is characterized by the formation of mucositis which includes redness, pain and ulcers in the mouth and back of the throat. OPC survivors who have successful treatment of their tumors often develop permanent swallowing, speaking and range of motion issues that may be linked back to the inability to eat and/or drink caused by SOM during their chemoradiotherapy treatment. Clonidine may inhibit the production of cytokines that cause SOM and clonidine HCl mucoadhesive buccal tablet (MBT) has been designed to deliver sustained high levels of clonidine in the oral cavity, potentially decreasing cytokine production and leading to a decrease in the incidence of SOM. Clonidine HCl MBT is a once per day treatment provided as a tablet that a patient may self-administer to the gums, where it sticks tightly to release clonidine over many hours. The primary objective of this Phase 2b/3 study is to evaluate whether clonidine HCl MBT is more effective than placebo MBT in decreasing the incidence of SOM.

For more information call 501-686-8288 or email CancerClinicalTrials@uams.edu

Posted by Chadley Uekman on August 3, 2022

Filed Under: Clinical Trials

Winthrop P. Rockefeller Cancer Institute LogoWinthrop P. Rockefeller Cancer InstituteWinthrop P. Rockefeller Cancer Institute
Address: 449 Jack Stephens Dr., Little Rock, AR 72205
Parking Deck: 4018 W Capitol Ave., Little Rock, AR 72205
Appointments: (501) 296-1200
Referring Physicians: (501) 686-6080
  • Facebook
  • Twitter
  • Instagram
  • YouTube
  • LinkedIn
  • Pinterest
  • Disclaimer
  • Terms of Use
  • Privacy

© 2022 University of Arkansas for Medical Sciences